BillionToOne AAQS

Mitä BillionToOne tekee? BillionToOne Inc generates revenue through its Quantitative Counting Template (QCT) molecular counter platform, the only technology capable of counting DNA molecules at the single-count level. The company's product UNITY offers noninvasive prenatal screening for cystic fibrosis (CF) and spinal muscular atrophy (SMA) using maternal blood samples. Healthcare providers and genetic testing laboratories purchase the QCT platform and UNITY services to detect genetic disease risks early. The primary customer segments include hospitals, clinics specializing in obstetrics and genetics, and diagnostic laboratories seeking advanced molecular diagnostics solutions. UNITY is marketed as a single-sample test for fetal cell-free DNA analysis, targeting prenatal care providers who require precise genetic risk assessment. The QCT platform is sold to laboratories needing high-precision DNA counting capabilities for research and clinical applications. These services are utilized by healthcare facilities focused on maternal-fetal health and genetic disorder screening. The company's revenue streams are derived from licensing the QCT platform to diagnostic institutions and providing the UNITY screening service directly to healthcare providers. No additional products or services are mentioned in the business description beyond these two offerings. BillionToOne on yksi Eurpooliin suosituimmista yhtiöistä.